Daytime Glibenclamide and Bedtime NPH Insulin Compared to Intensive Insulin Treatment in Secondary Sulphonylurea Failure: A 1-Year Follow-up

Diabetic Medicine

Volumn 13, Issue 5, 1996, Pages 471-477

  Clauson, P ^a   Karlander, S ^b   Steen, L ^c   Efendic, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Motala Hospital

^c Department of Medicine ^*  (Sweden)

Author keywords

Insulin treatment; Non insulin dependent diabetes mellitus; Treatment failure

Indexed keywords

CREATININE; GLIBENCLAMIDE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN, NEUTRAL; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; EDUCATION; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; ALBUMINURIA; ANALYSIS OF VARIANCE; BLOOD; BODY MASS; COMPARATIVE STUDY; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT FAILURE;

AGED; ALBUMINURIA; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE; TRIGLYCERIDES;

EID: 0029664761     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199605)13:5<471::AID-DIA103>3.0.CO;2-T     Document Type: Article

References (27)

1. Lebovitz H, Feinglos M. Sulphonyluren drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1978; 1: 189-198.
2. Scheen AJ, Lefèbvre PJ. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract 1989; 6: S33-S44.
3. DeFronzo R, Ferranini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
4. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulphonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992; 15: 953-959.
5. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimes in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433.
6. Gutniak M, Karlander S-G, Efendir S. Glyburide decreases insulin requirement, increases B-cell response to mixed meal, and does not affect insulin sensitivity. Effects of short and long-term combined treatment in secondary failure to sulphonylurea. Diabetes Care 1987; 10: 545-553.
7. Shank M, Prato Sd, DeFronzo R. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44: 165-172.
8. Rossetti L, Giaccari A, DeFronzo R. Glucose toxicity. Diabetes Care 1990; 13: 610-630.
9. Leahy JL, Bonner-Weir S, Weir G. b-Cell dysfunction induced by chronic hyperglyacemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442-455.
10. 2+ precipitation procedure for quantitation of high density-lipoprotein cholesterol. Clinical Chemistry 1982; 28: 1379-1388.
11. Chappel D, Carrera A. A short evaluation of two protein analysers. The Clinical Biochemist, Newsletter 1987; June 16-20.
12. Groop L, Botazzo G, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 1985; 35: 237-241.
13. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark Å, Sundqvist G. b-Cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis diabetes in type II diabetic patients. Diabetes Care 1993; 16: 902-910.
14. Riddle MC. New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet 1985; 192-195.
15. Riddle M, Hart J, Bouma D, Phillipson B, Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for a subpopulation of type II diabetic subjects. Diabetes Care 1969; 12: 623-629.
16. Efendic S, Östensson C-G. Hormonal responses and future treatment of non-insulin-dependent diabetes mellitus (NIDDM). J Int Med 1993; 234: 127-138.
17. Taskinen M-R, Sane T, Helve E, Kanonen S-L, Nikkilä E, Yki-Järvinen H. Bedtime insulin injection for suppression of overnight free-fatty acid, blood glucose and glucose production in NIDDM. Diabetes 1989; 5: 849-855.
18. Casner PR. Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double blind, placebo-controlled trial. Clin Pharmacol Ther 1988; 44: 594-603.
19. Quatraro A, Consoli G, Ceriello A, Guigliano D. Combined insulin and sulphonylurea therapy in non-insulin dependent diabetes with secondary failure to oral drugs; a one year follow-up. Diabete Metab (Paris) 1986; 12: 315-318.
20. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18: 23-28.
21. Garvey W, Olefsky J, Griffin J, Hamman R, Kolterman O. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-234.
22. Lindström T, Arnqvist H, Olsson A. Effect of different insulin regimes on plasma lipoprotein and apolipoprotein concentrations in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 1990; 81: 137-144.
23. Paisey R, Elkeles R, Hambley J, Magill P. The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia 1978; 15: 81-85.
24. Agardh C, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982; 5: 322-325.
25. Abrams J, Ginsberg H, Grundy S. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 1982; 31: 903-910.
26. Hollenbeck C, Chen Y-D, Greenfeld M, Lardinois C, Reaven G. Reduced plasma high density lipoprotein cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1986; 62: 605-608.
27. Pfeifer M, Brunzell J, Best J, Judzewitsch R, Halter J, Porte J. The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familiar hypertriglyceridemia. Diabetes 1983; 32: 525-531.